The Drug-Induced Respiratory Disease Website and App

Frequency - Incidence

Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

I.a

Pneumonitis (ILD), acute and/or severe (may produce the ARDS pattern)

Publications

Galván OP, Moltó HP, Fabià-Mayans A, Xicoy B, Mate JL, Martí PR

Hydroxyurea-Induced Pneumopathy in a Patient With Myeloproliferative Syndrome.

Clinical medicine insights. Case reports. 2018;11:1179547618770688

Girard A, Ricordel C, Poullot E, Claeyssen V, Decaux O, Desrues B, Delaval P, Jouneau S

[Hydroxyurea-induced pneumonia].

Revue des maladies respiratoires. 2014;31(5):430-4

Blanc PL, Joasson JM, Hammoud H, Matussière Y

[Acute interstitial pneumopathy with fever caused by hydroxyurea].

Presse medicale (Paris, France : 1983). 2000;29(5):242-5

Hennemann B, Bross KJ, Reichle A, Andreesen R

Acute alveolitis induced by hydroxyurea in a patient with myeloproliferative syndrome.

Annals of hematology. 1993;67(3):133-4

Kavuru MS, Gadsden T, Lichtin A, Gephardt G

Hydroxyurea-induced acute interstitial lung disease.

Southern medical journal. 1994;87(7):767-9

Jackson GH, Wallis J, Ledingham J, Lennard A, Proctor SJ

Hydroxyurea-induced acute alveolitis in a patient with chronic myeloid leukaemia.

Cancer chemotherapy and pharmacology. 1990;27(2):168-9